Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 709-716

  Seto, Wai Kay ^a   Liu, Kevin ^a,b   Wong, Danny Ka Ho ^a,b   Fung, James ^a   Huang, Fung Yu ^a   Hung, Ivan Fan Ngai ^a   Lai, Ching Lung ^a,b   Yuen, Man Fung ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Tenofovir HBsAg Surface antigen Nucleoside analogue Nucleotide analogue TDF

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASIAN; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SEROCONVERSION; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; VIREMIA;

ALANINE AMINOTRANSFERASE; ALT; ANTI-HBS; ANTIBODY TO THE HEPATITIS B SURFACE ANTIGEN; CHB; CHRONIC HEPATITIS B; HBEAG; HBSAG; HBV; HEPATITIS B E ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; NUCLEOSIDE ANALOGUE; NUCLEOTIDE ANALOGUE; SURFACE ANTIGEN; TDF; TENOFOVIR; TENOFOVIR DISOPROXIL FUMARATE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; KINETICS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; YOUNG ADULT;

EID: 84884416192     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.06.007     Document Type: Article

References (30)

1. E.J. Heathcote, P. Marcellin, M. Buti, E. Gane, R.A. De Man, and Z. Krastev Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
2. F. van Bommel, R.A. de Man, H. Wedemeyer, K. Deterding, J. Petersen, and P. Buggisch Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
3. S.J. Patterson, J. George, S.I. Strasser, A.U. Lee, W. Sievert, and A.J. Nicoll Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B Gut 60 2011 247 254
4. A. Snow-Lampart, B. Chappell, M. Curtis, Y. Zhu, F. Myrick, and J. Schawalder No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
5. W. Chotiyaputta, and A.S. Lok Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection J Viral Hepat 16 2009 91 93
6. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
7. J.W. Ward, A.S. Lok, D.L. Thomas, H.B. El-Serag, and W.R. Kim Report on a single-topic conference on "Chronic viral hepatitis-strategies to improve effectiveness of screening and treatment" Hepatology 55 2012 307 315
8. R. Zoutendijk, H.L. Zaaijer, T.E. de Vries-Sluijs, J.G. Reijnders, J.W. Mulder, and F.P. Kroon Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV J Infect Dis 206 2012 974 980
9. M.F. Yuen, W.K. Seto, D.H. Chow, K. Tsui, D.K. Wong, and V.W. Ngai Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antivir Ther 12 2007 1295 1303
10. M.F. Yuen, W.K. Seto, J. Fung, D.K. Wong, J.C. Yuen, and C.L. Lai Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety Am J Gastroenterol 106 2011 1264 1271
11. W.K. Seto, D.K. Wong, J. Fung, P.P. Ip, J.C. Yuen, and I.F. Hung High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B PLoS One 7 2012 e43087
12. T.C. Tseng, C.J. Liu, H.C. Yang, T.H. Su, C.C. Wang, and C.L. Chen High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load Gastroenterology 142 2012 1140 1149
13. W.K. Seto, D.K. Wong, J. Fung, I.F. Hung, D.Y. Fong, and J.C. Yuen A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance Hepatology 56 2012 812 819
14. M.R. Brunetto, F. Oliveri, P. Colombatto, F. Moriconi, P. Ciccorossi, and B. Coco Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers Gastroenterology 139 2010 483 490
15. K. Wursthorn, M. Jung, A. Riva, Z.D. Goodman, P. Lopez, and W. Bao Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
16. J. Fung, C.L. Lai, J. Young, D.K. Wong, J. Yuen, and W.K. Seto Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment Am J Gastroenterol 106 2011 1766 1773
17. J. Jaroszewicz, H. Ho, A. Markova, K. Deterding, K. Wursthorn, and S. Schulz Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues Antivir Ther 16 2011 915 924
18. W.E. Delaney, A.S. Ray, H. Yang, X. Qi, S. Xiong, and Y. Zhu Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus Antimicrob Agents Chemother 50 2006 2471 2477 (Pubitemid 43993188)
19. S. Villet, C. Pichoud, G. Billioud, L. Barraud, S. Durantel, and C. Trepo Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure J Hepatol 48 2008 747 755
20. W.K. Seto, D.K. Wong, J. Fung, I.F. Hung, J.C. Yuen, and T. Tong Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B Hepatol Int 7 2013 119 126
21. C.A. Bill, and J. Summers Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration Proc Natl Acad Sci USA 101 2004 11135 11140 (Pubitemid 38989596)
22. C.L. Lai, and M.F. Yuen Profound suppression of hepatitis B virus replication with lamivudine J Med Virol 61 2000 367 373 (Pubitemid 30368540)
23. E.K. Manesis, G.V. Papatheodoridis, D.G. Tiniakos, E.S. Hadziyannis, O.P. Agelopoulou, and T. Syminelaki Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B J Hepatol 55 2011 61 68
24. D.K. Wong, W.K. Seto, J. Fung, P.P. Ip, F.Y. Huang, and C.L. Lai Reduction of hepatitis B surface antigen and covalently closed cirular DNA by nucleos(t)ide analogues of different potency Clin Gastroenterol Hepatol 11 2013 1004 1010
25. D.K. Wong, M.F. Yuen, V.W. Ngai, J. Fung, and C.L. Lai One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels Antivir Ther 11 2006 909 916 (Pubitemid 44736182)
26. H.L. Chan, V.W. Wong, G.L. Wong, C.H. Tse, H.Y. Chan, and J.J. Sung A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B Hepatology 52 2010 1232 1241
27. T.C. Tseng, C.J. Liu, T.H. Su, C.C. Wang, C.L. Chen, and P.J. Chen Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters Gastroenterology 141 2011 517 525
28. G.L. Wong, V.W. Wong, H.Y. Chan, P.C. Tse, J. Wong, and A.M. Chim Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years Aliment Pharmacol Ther 35 2012 1326 1335
29. J.G. Reijnders, V. Rijckborst, M.J. Sonneveld, S.M. Scherbeijn, C.A. Boucher, and B.E. Hansen Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir J Hepatol 54 2011 449 454
30. R.G. Gish, T.T. Chang, C.L. Lai, R.A. de Man, A. Gadano, and C. Llamoso Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir Antivir Ther 2013 [in press]